Opendata, web and dolomites

NeuroPa SIGNED

Targeting the brain sigma-1 receptor: A paradigm shift for the treatment of neuro-degenerative disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeuroPa project word cloud

Explore the words cloud of the NeuroPa project. It provides you a very rough idea of what is the project "NeuroPa" about.

an    full    pressing    sales    qualities    total    abandoned    projected    patent    provides    neurodegeneration    sit    regulator    company    orphan    reflected    aging    disease    2b    neuropa    compound    progression    safety    trillion    symptoms    repositioning    investor    suffering    commercial    patients    profile    feasibility    peak    original    spasms    market    impressive    sigma    proven    comparably    als    data    amyotrophic    critical    candidates    severity    western    tries    speaking    protection    paralysis    multiple    euros    lateral    competing    fail    diseases    strategy    proof    swallowing    treatment    addressable    drugs    previously    positioning    regulatory    drug    neurodegenerative    clinical    excellent    prevalent    urgent    sclerosis    depression    alzheimer    motor    slow    2018    changing    modifying    lethality    muscle    ad    population    treatments    effect    brain    humans    million    efficacy    asset    candidate    life    sigmathera    trials    symptomatic    pipeline    161    societies    close    worldwide    receptor    biggest    french   

Project "NeuroPa" data sheet

The following table provides information about the project.

Coordinator
SIGMATHERA SAS 

Organization address
address: AGROPOLIS 2, 2196 BOULEVARD DE LA LIRONDE
city: MONTFERRIER SUR LEZ
postcode: 34980
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIGMATHERA SAS FR (MONTFERRIER SUR LEZ) coordinator 50˙000.00

Map

 Project objective

An increasingly aging population suffering from neurodegenerative diseases represents one of the biggest challenges for Western societies. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease with over 50 million patients worldwide and an estimated cost of 1 trillion euros in 2018. In addition, orphan neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) have a comparably urgent need for treatment, because of the severity and life changing effect of the motor symptoms (muscle spasms, speaking and swallowing problems, full paralysis and lethality). As current treatments are only symptomatic and fail to slow down the disease progression, there is a pressing need for novel effective disease-modifying treatments.

SigmaThera is a French company that tries to address the need for effective treatments for neurodegenerative diseases by focusing on the repositioning of drug candidates: applying the proven qualities of previously developed drugs for new diseases. For our lead compound SIT-161 with an excellent safety profile in humans (the candidate was abandoned after original Phase 2 trials for major depression) we have obtained impressive proof-of-concept data and patent protection for the treatment of neurodegenerative diseases, including AD & ALS. The drug targets a brain sigma-1 receptor, a critical regulator of multiple processes in neurodegeneration and provides unique efficacy and safety compared to other competing candidates in the pipeline. The high commercial potential of the drug is reflected in the €6.2B total addressable market and projected peak sales of €2B. In the NeuroPa project, SigmaThera will investigate market positioning, clinical and regulatory feasibility, future patent strategy and investor strategy to bring this promising asset close to market implementation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEUROPA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEUROPA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More